Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness

被引：26

作者：

Castro, Sara Guerreiro ^{[2
]}

Isenberg, David A. ^{[1
]}

机构：

[1] UCL, Ctr Rheumatol, Room 424,4th Floor Rayne Bldg,5 Univ St, London WC1E 6JF, England

[2] Hosp Curry Cabral, Ctr Hosp Lisboa Cent, Internal Med Dept 7 2, Autoimmune Dis Unit, Lisbon, Portugal

来源：

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | 2017年 / 9卷 / 03期

关键词：

belimumab; biologic therapy; immunosuppressive agents; systemic lupus erythematosus; B-LYMPHOCYTE STIMULATOR; DISEASE-ACTIVITY; MONOCLONAL-ANTIBODY; SAFETY; INHIBITOR;

D O I：

10.1177/1759720X17690474

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.

引用

页码：75 / 85

页数：11

共 35 条

[21] Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus [J].

Jacobi, AM ;

Odendahl, M ;

Reiter, K ;

Bruns, A ;

Burmester, GR ;

Radbruch, A ;

Valet, G ;

Lipsky, PE ;

Dörner, T .

ARTHRITIS AND RHEUMATISM, 2003, 48 (05) :1332-1342

[22] Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials [J].

Manzi, Susan ;

Sanchez-Guerrero, Jorge ;

Merrill, Joan T. ;

Furie, Richard ;

Gladman, Dafna ;

Navarra, Sandra V. ;

Ginzler, Ellen M. ;

D'Cruz, David P. ;

Doria, Andrea ;

Cooper, Simon ;

Zhong, Z. John ;

Hough, Douglas ;

Freimuth, William ;

Petri, Michelle A. .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) :1833-1838

[23] Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus [J].

Merrill, Joan T. ;

Ginzler, Ellen M. ;

Wallace, Daniel J. ;

Mckay, James D. ;

Lisse, Jeffrey R. ;

Aranow, Cynthia ;

Wellborne, Frank R. ;

Burnette, Michael ;

Condemi, John ;

Zhong, Z. John ;

Pineda, Lilia ;

Klein, Jerry ;

Freimuth, William W. .

ARTHRITIS AND RHEUMATISM, 2012, 64 (10) :3364-3373

[24]

National Institute for Health and Care Excellence, 2016, BELIMUMAB TREATING A

[25] Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial [J].

Navarra, Sandra V. ;

Guzman, Renato M. ;

Gallacher, Alberto E. ;

Hall, Stephen ;

Levy, Roger A. ;

Jimenez, Renato E. ;

Li, Edmund K-M ;

Thomas, Mathew ;

Kim, Ho-Youn ;

Leon, Manuel G. ;

Tanasescu, Coman ;

Nasonov, Eugeny ;

Lan, Joung-Liang ;

Pineda, Lilia ;

Zhong, Z. John ;

Freimuth, William ;

Petri, Michelle A. .

LANCET, 2011, 377 (9767) :721-731

[26] Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus [J].

Petri, Michelle ;

Stohl, William ;

Chatham, Winn ;

McCune, W. Joseph ;

Chevrier, Marc ;

Ryel, Jeff ;

Recta, Virginia ;

Zhong, John ;

Freimuth, William .

ARTHRITIS AND RHEUMATISM, 2008, 58 (08) :2453-2459

[27] Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis [J].

Pierotti, Francesca ;

Palla, Ilaria ;

Treur, Maarten ;

Pippo, Lara ;

Turchetti, Giuseppe .

PLOS ONE, 2015, 10 (10)

[28]

Specchia ML, 2014, BIOMED RES INT, V2014, P704207

[29] Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus [J].

Stohl, William ;

Hiepe, Falk ;

Latinis, Kevin M. ;

Thomas, Mathew ;

Scheinberg, Morton A. ;

Clarke, Ann ;

Aranow, Cynthia ;

Wellborne, Frank R. ;

Abud-Mendoza, Carlos ;

Hough, Douglas R. ;

Pineda, Lilia ;

Migone, Thi-Sau ;

Zhong, Z. John ;

Freimuth, William W. ;

Chatham, W. Winn .

ARTHRITIS AND RHEUMATISM, 2012, 64 (07) :2328-2337

[30] Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials [J].

Strand, Vibeke ;

Levy, Roger A. ;

Cervera, Ricard ;

Petri, Michelle A. ;

Birch, Helen ;

Freimuth, William W. ;

Zhong, Z. John ;

Clarke, Ann E. .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (05) :838-844

← 1 2 3 4 →